Juvelook Receives Regulatory Approval in Russia; Launch Event in Moscow Highlights Global Expansion Strategy

Juvelook Receives Regulatory Approval in Russia; Launch Event in Moscow Highlights Global Expansion Strategy

VAIM is pleased to announce that its flagship skin booster Juvelook has officially received medical device approval in Russia, marking a key advancement in the company’s international expansion. To commemorate this regulatory achievement, VAIM held a launch event in Moscow, attended by leading local dermatologists, aesthetic practitioners, and industry professionals.

Juvelook is an innovative collagen-stimulating injectable combining biodegradable PDLLA (Poly D,L-lactide) microspheres with hyaluronic acid (HA). Designed for direct dermal injection, the product stimulates natural collagen production, enhances skin elasticity, and improves overall skin quality. Juvelook has already received approval from the Korean Ministry of Food and Drug Safety (MFDS) and has obtained CE certification in Europe.

The Moscow launch event featured clinical lectures and live demonstrations by aesthetic experts, highlighting Juvelook’s safety, efficacy, and practical application. Attendees expressed strong interest in the product’s benefits, underscoring its growth potential within Russia’s rapidly evolving aesthetic medicine landscape.

“Russia is a strategically important market in the global aesthetic medicine sector, with a steadily increasing demand for cosmetic procedures,” said a VAIM spokesperson. “This launch represents a pivotal milestone in our global roadmap, enabling us to expand further into CIS (Commonwealth of Independent States) regions and strengthen VAIM’s global presence.”

This latest regulatory approval marks another step forward in VAIM’s commitment to delivering advanced regenerative solutions to patients and practitioners worldwide.

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM Global, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM Global currently has product export contracts with 72 countries.